 |
市场调查报告书
商品编码
1684689
溃疡性结肠炎市场机会、成长动力、产业趋势分析与 2025 - 2034 年预测Ulcerative Colitis Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
||||||
2024 年全球溃疡性结肠炎市场规模达到 80 亿美元，并将稳定扩张，预计 2025 年至 2034 年的复合年增长率为 5.6%。这一增长主要得益于溃疡性结肠炎发病率的不断上升，而城市化、饮食习惯的改变和环境变化导致溃疡性结肠炎发病率持续上升。随着越来越多的人接受西方化的生活方式，不良饮食、压力和污染等因素导致发炎性肠道疾病（IBD）（包括溃疡性结肠炎）的发生率上升。全球有数百万人受到影响，对有效和长期治疗方案的需求正在增加。
医学研究的进步促进了新疗法的开发，从而提供了更好的疾病管理和改善患者预后。製药公司正在积极投资新的药物配方，包括生物製剂和JAK抑制剂，以提供更有针对性的治疗。此外，医疗保健系统更加重视早期诊断和干预，从而提高患者意识并及时提供医疗护理。对以患者为中心的治疗方案（包括个人化医疗和联合疗法）的日益关注也在推动市场创新。新药的监管批准和现有药物适应症的扩大进一步促进了市场成长，为药品製造商和医疗保健提供者创造了有利可图的机会。
| 市场范围 | |
|---|---|
| 起始年份 | 2024 |
| 预测年份 | 2025-2034 |
| 起始值 | 80亿美元 |
| 预测值 | 135亿美元 |
| 复合年增长率 | 5.6% |
根据药物类型，市场分为氨基水杨酸盐、生物製剂、皮质类固醇、Janus 激酶 (JAK) 抑制剂、免疫抑制剂等。 2024 年，氨基水杨酸盐部门的收入为 28 亿美元，反映了其广泛用于治疗轻度至中度溃疡性结肠炎的第一线治疗。这些抗发炎药物在减轻症状和维持缓解方面非常有效，因此成为许多患者的首选。它们能够提供长期缓解且没有显着副作用，这使得它们在市场上占据强大的地位。随着轻症确诊率的上升，氨基水杨酸盐的需求依然旺盛，确保了其在市场上继续占据主导地位。
给药方法在患者偏好和治疗依从性方面起着至关重要的作用。市场分为口服和注射疗法，其中口服药物在 2024 年占 52.2% 的份额。许多常用的治疗药物，包括氨基水杨酸盐、JAK 抑制剂和免疫抑制剂，都有口服剂型，这对患者来说是一种方便的选择。由于口服药物易于自行给药、成本效益高以及减少频繁就医的需要，因此成为首选。製药公司不断改进药物输送系统，提高口服治疗的生物利用度和疗效，进一步巩固该领域在市场上的地位。
2024 年美国溃疡性结肠炎市场价值为 30 亿美元，成为全球市场成长最大的区域贡献者之一。美国溃疡性结肠炎发生率高，对先进治疗方案的需求庞大。完善的医疗保健基础设施、增加的研发资金以及积极主动的疾病意识方法加速了市场扩张。
目录
第 1 章：方法论与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业衝击力
- 成长动力
- 溃疡性结肠炎盛行率不断上升
- 扩大治疗选择
- 提高认识和诊断
- 产业陷阱与挑战
- 治疗费用高
- 副作用和安全问题
- 成长动力
- 成长潜力分析
- 监管格局
- 管道分析
- 波特的分析
- PESTEL 分析
第四章：竞争格局
- 介绍
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 策略仪表板
第 5 章：市场估计与预测：按药物类型，2021 年至 2034 年
- 主要趋势
- 氨基水杨酸盐
- 生物製剂
- 皮质类固醇
- Janus 激酶 (JAK) 抑制剂
- 免疫抑制剂
- 其他药物类型
第 6 章：市场估计与预测：按疾病类型，2021 – 2034 年
- 主要趋势
- 直肠乙状结肠炎
- 溃疡性直肠炎
- 左侧结肠炎
- 全结肠炎或全身结肠炎
- 暴发性结肠炎
第 7 章：市场估计与预测：按管理路线，2021 年至 2034 年
- 主要趋势
- 口服
- 注射剂
第 8 章：市场估计与预测：按配销通路，2021 年至 2034 年
- 主要趋势
- 医院药房
- 零售药局
- 网路药局
第 9 章：市场估计与预测：按地区，2021 年至 2034 年
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 荷兰
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
第十章：公司简介
- AbbVie
- Bausch Health Companies
- Bristol Myers Squibb
- Eli Lilly and Company
- Johnson & Johnson
- Merck
- Mitsubishi Tanabe Pharma Corporation
- Novartis
- Pfizer
- Sun Pharmaceutical Industries
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries
The Global Ulcerative Colitis Market reached USD 8 billion in 2024 and is set to experience steady expansion, with a projected CAGR of 5.6% from 2025 to 2034. This growth is largely fueled by the increasing prevalence of ulcerative colitis, which continues to rise due to urbanization, evolving dietary habits, and environmental changes. As more people adopt Westernized lifestyles, factors such as poor diet, stress, and pollution have contributed to a higher incidence of inflammatory bowel diseases (IBD), including ulcerative colitis. With millions affected worldwide, the demand for effective and long-term treatment solutions is on the rise.
Advancements in medical research have led to the development of novel therapies that offer better disease management and improved patient outcomes. Pharmaceutical companies are actively investing in new drug formulations, including biologics and JAK inhibitors, to provide more targeted treatments. Additionally, healthcare systems are placing greater emphasis on early diagnosis and intervention, leading to increased patient awareness and timely medical care. The growing focus on patient-centric treatment plans, including personalized medicine and combination therapies, is also driving innovation within the market. Regulatory approvals for new drugs and expanded indications for existing medications are further contributing to market growth, creating lucrative opportunities for drug manufacturers and healthcare providers.
| Market Scope | |
|---|---|
| Start Year | 2024 |
| Forecast Year | 2025-2034 |
| Start Value | $8 Billion |
| Forecast Value | $13.5 Billion |
| CAGR | 5.6% |
The market is categorized by drug type into aminosalicylates, biologics, corticosteroids, Janus kinase (JAK) inhibitors, immunosuppressants, and others. In 2024, the aminosalicylates segment generated USD 2.8 billion, reflecting its widespread use as a first-line treatment for mild to moderate ulcerative colitis. These anti-inflammatory drugs are highly effective in reducing symptoms and maintaining remission, making them a preferred option for many patients. Their ability to provide long-term relief without significant side effects has contributed to their strong market presence. With the increasing diagnosis rate of mild cases, the demand for aminosalicylates remains robust, ensuring their continued dominance in the market.
The method of administration plays a critical role in patient preference and treatment compliance. The market is segmented into oral and injectable therapies, with oral medications capturing a 52.2% share in 2024. Many commonly prescribed treatments, including aminosalicylates, JAK inhibitors, and immunosuppressants, are available in oral formulations, making them a convenient option for patients. The ease of self-administration, cost-effectiveness, and reduced need for frequent medical visits make oral drugs the preferred choice. Pharmaceutical companies continue to refine drug delivery systems, enhancing the bioavailability and efficacy of oral treatments, further strengthening this segment's position in the market.
The United States ulcerative colitis market was valued at USD 3 billion in 2024, making it one of the largest regional contributors to global market growth. The high prevalence of ulcerative colitis in the U.S. has driven significant demand for advanced treatment options. A well-established healthcare infrastructure, increased funding for research and development, and a proactive approach to disease awareness have accelerated market expansion.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of ulcerative colitis
- 3.2.1.2 Expanding treatment options
- 3.2.1.3 Increasing awareness and diagnosis
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High treatment costs
- 3.2.2.2 Side effects and safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Aminosalicylates
- 5.3 Biologics
- 5.4 Corticosteroids
- 5.5 Janus kinase (JAK) inhibitors
- 5.6 Immunosuppressants
- 5.7 Other drug types
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Proctosigmoiditis
- 6.3 Ulcerative proctitis
- 6.4 Left-sided colitis
- 6.5 Pancolitis or universal colitis
- 6.6 Fulminant colitis
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Injectable
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Netherlands
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
Chapter 10 Company Profiles
- 10.1 AbbVie
- 10.2 Bausch Health Companies
- 10.3 Bristol Myers Squibb
- 10.4 Eli Lilly and Company
- 10.5 Johnson & Johnson
- 10.6 Merck
- 10.7 Mitsubishi Tanabe Pharma Corporation
- 10.8 Novartis
- 10.9 Pfizer
- 10.10 Sun Pharmaceutical Industries
- 10.11 Takeda Pharmaceutical Company Limited
- 10.12 Teva Pharmaceutical Industries
